Coherus Oncology, Inc. Debt Conversion, Converted Instrument, Amount
Coherus Oncology, Inc. (CHRS) reported Debt Conversion, Converted Instrument, Amount of $10.63 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2015-03-23
- Coherus Oncology, Inc. debt conversion, converted instrument, amount for fiscal 2012 was $10.63M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2012-12-31 | $10.63M 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |